Clinical Trial Update: Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy [Phase 3]

View source ↗

Summary

An open-label extension of avacincaptad pegol in geographic atrophy has completed Phase 3, with results posted on April 14, 2026. The study is sponsored by Aste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• Avacincaptad pegol (avacincaptad pegol)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Geographic Atrophy, Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2026-04-14